Design Therapeutics (DSGN) Price/OCF Ratio: History & Chart

Design Therapeutics, Inc.(DSGN)

Biotechnology · Carlsbad, CA

$11.97-0.45 (-3.62%)

Delayed quote: Oct 6, 2026, 1:45 PM EDT

About Design Therapeutics, Inc.

Design Therapeutics, Inc. is a biopharmaceutical company in the preclinical phase that focuses on creating treatments for genetic conditions stemming from nucleotide repeat expansions. Its current pipeline targets Friedreich's Ataxia (FA), a severe, progressive, monogenic, and autosomal recessive disease. FA primarily impairs mitochondrial function across various organ systems, resulting in neurological, cardiac, and metabolic complications. Another significant area of development is Myotonic Dystrophy Type-1 (DM1). This is a progressive, dominantly inherited monogenic neuromuscular illness that impacts skeletal muscle, the heart, brain, and other bodily systems. Beyond these, the company is advancing its GeneTAC product candidate platform to address an array of other monogenic conditions caused by nucleotide repeat expansions. These include Fragile X syndrome, various spinocerebellar ataxias, amyotrophic lateral sclerosis (ALS), frontotemporal dementia, Huntington's disease, and spinobulbar muscular atrophy. Established in 2017, Design Therapeutics, Inc. maintains its headquarters in Carlsbad, California.

Carlsbad, CA

55 employees

www.designtx.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Pratik Shah

View full financials

NAME	MARKET CAP	PRICE/OCF RATIO	TTM	3Y	5Y
Design Therapeutics, Inc. (DSGN)	$747.61M	N/A	N/A	N/A	N/A
Attovia Therapeutics, Inc. (ATTO)vs ›	$757.76M	N/A	N/A	N/A	N/A
Mesa Laboratories, Inc. (MLAB)vs ›	$765.23M	13.74	12.12	13.02	20.17
Candel Therapeutics, Inc. (CADL)vs ›	$727.94M	N/A	N/A	N/A	N/A
Apnimed, Inc. (APMD)vs ›	$765.00M	N/A	N/A	N/A	N/A
Achieve Life Sciences, Inc. (ACHV)vs ›	$728.53M	N/A	4.41	4.41	4.41
Lexicon Pharmaceuticals, Inc. (LXRX)vs ›	$768.46M	N/A	2.47	2.47	6.38
Sana Biotechnology, Inc. (SANA)vs ›	$771.06M	N/A	N/A	N/A	N/A
Cytek Biosciences, Inc. (CTKB)vs ›	$720.22M	N/A	24.89	136.95	245.47
Faeth Therapeutics, Inc. (FTH)vs ›	$713.56M	N/A	N/A	N/A	N/A

NAME

MARKET CAP

PRICE/OCF RATIO

TTM

Design Therapeutics, Inc. (DSGN)

$747.61M

N/A

Attovia Therapeutics, Inc. (ATTO)vs ›

$757.76M

N/A

Mesa Laboratories, Inc. (MLAB)vs ›

$765.23M

13.74

12.12

13.02

20.17

Candel Therapeutics, Inc. (CADL)vs ›

$727.94M

N/A

Apnimed, Inc. (APMD)vs ›

$765.00M

N/A

Achieve Life Sciences, Inc. (ACHV)vs ›

$728.53M

N/A

4.41

Lexicon Pharmaceuticals, Inc. (LXRX)vs ›

$768.46M

N/A

2.47

6.38

Sana Biotechnology, Inc. (SANA)vs ›

$771.06M

N/A

Cytek Biosciences, Inc. (CTKB)vs ›

$720.22M

N/A

24.89

136.95

245.47

Faeth Therapeutics, Inc. (FTH)vs ›

$713.56M

N/A

Price/OCF Ratio Formula & Definition

P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.

Price/OCF Ratio: N/A

DSGN Price/OCF Ratio Metrics

DSGN Competitors' Price/OCF Ratio

Operating Cash Flow Valuation

Price/OCF Ratio Formula & Definition

Related Metrics